EL7.AI
StocksMedium•4 November 2026•
1 min read

Royalty Pharma Raises 2026 Guidance Following 9% Growth in Portfolio Receipts

Key Facts

1Royalty Pharma reported a 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026.
2The company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3,500 million to $3,550 million.

Royalty Pharma reported a 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026. According to a statement released via GlobeNewswire, the company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3,500 million to $3,550 million. The upward revision follows strong performance in royalty receipts and the execution of the company's portfolio strategy.

RPRX closed at $66.4 on November 3, 2026, prior to the release of the financial results highlighting the company's operational momentum. As of September 30, 2026, Royalty Pharma held cash and cash equivalents of $514 million, with total debt at a principal value of $8.8 billion. During the third quarter, the company also repurchased approximately 1.5 million Class A ordinary shares for $87 million.

Open on chart